EUS Elastography for Predicting Cirrhotic-related Complications
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 4 Nov 2019
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- EUS elastography
- Record updated
- 19 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening
- Patients with suspected advanced liver fibrosis as detected by Fibroscan
- Patients with clinical evidence of hypersplenism
- Age > 18 years
- Written informed consent available
Who cannot take part
- Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome
- Patients with history of hepatocellular carcinoma
- Patients with history of liver transplant or TIPS or shunting surgery
- Patients with portal and/or mesenteric vein thrombosis
- Moribund patients from terminal illnesses
- Patients with terminal malignancy
- Contraindications for endoscopy
- Unable to provide written informed consent
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in recent decades. Current guidelines also advocate the use of Fibroscan® machine (EchoSens, Paris, France) to detect any advanced liver fibrosis as represented by high liver stiffness, for prediction of varices development.
Read full original descriptionShow less
Apart from liver stiffness, studies have shown that spleen stiffness (SS) has been proven another useful parameter to severity of underlying portal hypertension and liver cirrhosis. However, spleen stiffness measurement by Fibroscan® is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. It carries certain technical difficulty as well due to its deep-seated anatomical position.
Recently, the technique of endoscopic ultrasound elastography (EUS-E) has been described. It can overcome the limitations of Fibroscan by making measurements of liver and spleen stiffness through the gastric wall, which has a shorter distance than the abdominal wall. It also allows concomitant upper GI tract luminal examination, incorporating both esophagogastroduodenoscopy and elastography measurements into one procedure at the same time. This research study aims to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.
The group in the trial
- Study group
Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
Treatment: EUS elastography
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Study on the Utility of Endoscopic Ultrasound Elastography (EUS-E) for Predicting Cirrhotic-related Complications in Patients With Chronic Liver Diseases
- Record updated
- 19 March 2026